Skip to main content
SpringerLink
Log in

Innovators hit by ruling in dispute over cholesterol antibody patent

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The US Supreme Court decision in the Amgen vs. Sanofi patent dispute over PCSK9 inhibitors puts a decisive end to broad patents claiming rights over all molecules directed at a given target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Canterbury, UK

    Charlotte Harrison

Authors
  1. Charlotte Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harrison, C. Innovators hit by ruling in dispute over cholesterol antibody patent. Nat Biotechnol 41, 1035–1036 (2023). https://doi.org/10.1038/s41587-023-01894-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-01894-6

  • Springer Nature America, Inc.

Search

Navigation